{"id":"NCT01376908","sponsor":"BioMarin Pharmaceutical","briefTitle":"Kuvan® in Phenylketonuria Patients Less Than 4 Years Old","officialTitle":"A Phase IIIb, Multicentre, Open-Label, Randomized, Controlled Study of the Efficacy, Safety, and Population Pharmacokinetics of Sapropterin Dihydrochloride (Kuvan®) in Phenylketonuria (PKU) Patients <4 Years Old.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-06","primaryCompletion":"2014-07","completion":"2017-02-17","firstPosted":"2011-06-20","resultsPosted":"2016-05-12","lastUpdate":"2017-09-15"},"enrollment":56,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Phenylketonuria"],"interventions":[{"type":"DRUG","name":"Kuvan®","otherNames":["Sapropterin dihydrochloride"]},{"type":"OTHER","name":"Phenylalanine (Phe)-restricted diet","otherNames":[]}],"arms":[{"label":"Kuvan® + Phe-restricted diet","type":"EXPERIMENTAL"},{"label":"Phe-restricted diet alone","type":"OTHER"}],"summary":"This is a Phase 3b, multicenter, open-label, randomized, controlled study to evaluate efficacy, safety and population pharmacokinetics of sapropterin dihydrochloride (Kuvan®) in less than 4 year-old infants and children with phenylketonuria (PKU).","primaryOutcome":{"measure":"Dietary Phenylalanine (Phe) Tolerance at Week 26","timeFrame":"Week 26","effectByArm":[{"arm":"Kuvan® + Phe-restricted Diet","deltaMin":80.6,"sd":4.2},{"arm":"Phe-restricted Diet","deltaMin":50.1,"sd":4.3}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":15},"locations":{"siteCount":22,"countries":["Austria","Belgium","Czechia","Germany","Italy","Netherlands","Slovakia","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["34344399","28274234"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":27},"commonTop":["Pyrexia","Cough","Nasopharyngitis","Vomiting","Amino acid level decreased"]}}